Answers are grounded in this paper and cite their sources.
Clinical trial demonstrates improved pain relief and wound healing in diabetic foot ulcers using model-guided analgesia, indicating significant benefits of personalized care.
of 0.458 and an RMSE of 1.719 in the training set, while the validation-set RMSE, calibration intercept, calibration slope, and AUC for identifying high pain were 2.058, 1.414, 0.721, and 0.913, respectively. In stage 2 (72 cases), subjects were assigned to a control group and an intervention group. The intervention group received a personalized analgesic regimen based on model-derived risk stratification, while the control group received conventional analgesic care. After 4 weeks, the intervention group had a lower dressing-change VAS score than the control group (3.83 ± 1.61 vs 4.94 ± 1.91, P = 0.010), together with a higher overall adherence rate (86.11% vs 63.89%, P = 0.029), a higher ulcer area reduction rate (41.84% ± 11.01% vs 26.22% ± 7.55%, P < 0.001), and a shorter wound-healing time (32.0 [29.0-35.0] vs 38.0 [34.0-43.5] days, P < 0.001). The model showed useful discrimination for dressing-change pain, and the model-based personalized analgesic regimen improved short-term pain, adherence, and wound-related outcomes; however, external validation and further refinement of model calibration are required before routine clinical implementation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: